Efficacy and Safety of Drugs Used for Dyslipidemia
Article Sidebar
Published:
Sep 9, 2020
Main Article Content
Article Details
How to Cite
1.
Tubtim S. Efficacy and Safety of Drugs Used for Dyslipidemia. TFDJ [Internet]. 2020 Sep. 9 [cited 2024 Apr. 26];27(3):4-12. Available from: https://he01.tci-thaijo.org/index.php/fdajournal/article/view/244944
Section
Review Article
References
1. Talbert RL. Dyslipidemia. In: Dipiro JT,Talbert RL, Yee GC, Matzke GR, Wells BG,Michael Posey L, editors. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. USA:
McGraw-Hill;2017.p.271-98.
2. Wiggins BS, Morris PB. Dyslipidemia, Atherosclerosis and Coronary Heart Disease.In: Zeind CS, Carvalho MG, editors. Applied Therapeutics: The Clinical Use of Drugs. 11th ed.China: Wolters Kluwer;2018. p.100-31.
3. Sattar N, Preiss D, Murray HM, et al. Statin and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42.
4. Ko MJ, Jo AJ, Kim YJ, et al. Time-and dosedependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide
observational cohort study. J Am Heart Assoc 2019;8:e011320.
5. Richardson K, Schoen M, French B, et al.Statins and cognitive function: A systematic review. Ann Intern Med 2013;159:688-97.
6. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.
7. Bach RG, Cannon CP, Giugliano RP, et al.Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndromes among patients 75 years
or older: A secondary analysis of a randomized clinical trial. JAMA Cardiol 2019; 4(9):846-54.
8. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med 2011;365: 2255-67.
9. Landray MJ, Haynes R, Hopewell JC, et al. Effect of extended-release niacin with laropiprant in high risk patients. N Engl J Med 2014; 371:203-12.
10. Cuchel M, Meagher EA, Du Toit Theron H,et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in homozygous familial hypercholesterolemia:
A single-arm, open-label phase 3 study.Lancet 2013;381(9860): 40-6.
11. Blom DJ, Averna M, Meagher E, et al. Longterm efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide
in patients with homozygous familial hypercholesterolemia. Circulation 2017; 136:332-5.
12. Harada-Shiba M, Ikewaki K, Nohara A, et al.Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercho lesterolemia. J Atheroscler Thromb 2017;24:402-11.
13. Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): Result from the AEGR-733-301 Longterm extension trial. J Atheroscler Thromb 2019;26:368-77.
14. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380: 1022-32.
15. Goldberg AC, Leiter LA, Stores EG, et al.Effect of bempedoic acid VS placebo added to maximally tolerated Statins on low-density lipoprotein cholesterol in patients at high
risk for cardiovascular disease: The Clear Wisdom Randomized Clinical Trial. JAMA 2019; 322(18):1780-8.
16. Hu Y, Hu FB, Manson JE, et al. Marine omega-3 supplementation and cardiovascular disease. An updated meta-analysis of 13 randomized controlled trials involving
127,477 participants. J Am Heart Assoc 2019;
8:e013543.
17. Sabatine MS, Giugliano RP, Keech AC, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
18. Fogacci F, Ferri N, Toth PP, et al. Efficacy and safety of mipomersen: A systematic review and meta-analysis of randomized clinical trials. Drugs 2019;79:751-66.
19. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382(16):1507-19.
McGraw-Hill;2017.p.271-98.
2. Wiggins BS, Morris PB. Dyslipidemia, Atherosclerosis and Coronary Heart Disease.In: Zeind CS, Carvalho MG, editors. Applied Therapeutics: The Clinical Use of Drugs. 11th ed.China: Wolters Kluwer;2018. p.100-31.
3. Sattar N, Preiss D, Murray HM, et al. Statin and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42.
4. Ko MJ, Jo AJ, Kim YJ, et al. Time-and dosedependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide
observational cohort study. J Am Heart Assoc 2019;8:e011320.
5. Richardson K, Schoen M, French B, et al.Statins and cognitive function: A systematic review. Ann Intern Med 2013;159:688-97.
6. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.
7. Bach RG, Cannon CP, Giugliano RP, et al.Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndromes among patients 75 years
or older: A secondary analysis of a randomized clinical trial. JAMA Cardiol 2019; 4(9):846-54.
8. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med 2011;365: 2255-67.
9. Landray MJ, Haynes R, Hopewell JC, et al. Effect of extended-release niacin with laropiprant in high risk patients. N Engl J Med 2014; 371:203-12.
10. Cuchel M, Meagher EA, Du Toit Theron H,et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in homozygous familial hypercholesterolemia:
A single-arm, open-label phase 3 study.Lancet 2013;381(9860): 40-6.
11. Blom DJ, Averna M, Meagher E, et al. Longterm efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide
in patients with homozygous familial hypercholesterolemia. Circulation 2017; 136:332-5.
12. Harada-Shiba M, Ikewaki K, Nohara A, et al.Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercho lesterolemia. J Atheroscler Thromb 2017;24:402-11.
13. Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): Result from the AEGR-733-301 Longterm extension trial. J Atheroscler Thromb 2019;26:368-77.
14. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380: 1022-32.
15. Goldberg AC, Leiter LA, Stores EG, et al.Effect of bempedoic acid VS placebo added to maximally tolerated Statins on low-density lipoprotein cholesterol in patients at high
risk for cardiovascular disease: The Clear Wisdom Randomized Clinical Trial. JAMA 2019; 322(18):1780-8.
16. Hu Y, Hu FB, Manson JE, et al. Marine omega-3 supplementation and cardiovascular disease. An updated meta-analysis of 13 randomized controlled trials involving
127,477 participants. J Am Heart Assoc 2019;
8:e013543.
17. Sabatine MS, Giugliano RP, Keech AC, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
18. Fogacci F, Ferri N, Toth PP, et al. Efficacy and safety of mipomersen: A systematic review and meta-analysis of randomized clinical trials. Drugs 2019;79:751-66.
19. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382(16):1507-19.